Evolent Health Inc (EVH)vsNovartis AG ADR (NVS)
EVH
Evolent Health Inc
$4.19
+0.48%
HEALTHCARE · Cap: $508.77M
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2604% more annual revenue ($56.69B vs $2.10B). NVS leads profitability with a 22.5% profit margin vs -24.1%. EVH appears more attractively valued with a PEG of 1.93. EVH earns a higher WallStSmart Score of 52/100 (C-).
EVH
Buy52
out of 100
Grade: C-
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EVH.
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 46.9% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -131.8% — below average capital efficiency
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EVH
The strongest argument for EVH centers on Price/Book, Revenue Growth. Revenue growth of 46.9% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : EVH
The primary concerns for EVH are PEG Ratio, EPS Growth, Market Cap. Debt-to-equity of 2.53 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
EVH profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
EVH carries more volatility with a beta of 0.78 — expect wider price swings.
EVH is growing revenue faster at 46.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
EVH scores higher overall (52/100 vs 51/100) and 46.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evolent Health Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the United States. The company is headquartered in Arlington, Virginia.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?